Cargando…

Effect of cardiopulmonary bypass on activated partial thromboplastin time waveform analysis, serum procalcitonin and C-reactive protein concentrations

INTRODUCTION: Systemic inflammatory response syndrome (SIRS) is a frequent condition after cardiopulmonary bypass (CPB) and makes conventional biological tests fail to detect postoperative sepsis. Biphasic waveform (BPW) analysis is a new biological test derived from activated partial thromboplastin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delannoy, Bertrand, Guye, Marie-Laurence, Slaiman, Davy Hay, Lehot, Jean-Jacques, Cannesson, Maxime
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811936/ https://www.ncbi.nlm.nih.gov/pubmed/19912638 http://dx.doi.org/10.1186/cc8166

Ejemplares similares

Activated partial thromboplastin time waveform analysis as specific sepsis marker in cardiopulmonary bypass surgery
por: Schneider, Christian P, et al.
Publicado: (2010)

An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform
por: Katayama, Haruna, et al.
Publicado: (2018)

Reagent Effects on the Activated Partial Thromboplastin Time Clot Waveform Analysis: A Multi-Centre Study
por: Wong, Wan Hui, et al.
Publicado: (2023)

Activated Partial Thromboplastin Time and Mortality in Coronary Artery Bypass Grafting Patients
por: Zhang, HuanRui, et al.
Publicado: (2022)

Does cardiopulmonary bypass affect the procalcitonin level?
por: Kalay, F, et al.
Publicado: (2005)

Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism
por: Tan, Chuen Wen, et al.
Publicado: (2019)

Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis
por: Kanouchi, Kazunori, et al.
Publicado: (2021)

Arterial line waveform dampening, during weaning from cardiopulmonary bypass
por: Chao, Yupo, et al.
Publicado: (2022)

The Effect of Sugammadex on Prothrombin and Activated Partial Thromboplastin Time
por: Samara, Evangelia, et al.
Publicado: (2021)

Use of procalcitonin for identification of postoperative complications after coronary artery bypass surgery with cardiopulmonary bypass
por: Baysal, A, et al.
Publicado: (2014)

International normalized ratio and activated partial thromboplastin time testing
por: Chornenki, Nicholas L. J., et al.
Publicado: (2022)

Prediction of outcome in patients undergoing cardiac surgery on cardiopulmonary bypass using procalcitonin
por: Dörge, H, et al.
Publicado: (1999)

Ability of pleth variability index to detect hemodynamic changes induced by passive leg raising in spontaneously breathing volunteers
por: Keller, Geoffray, et al.
Publicado: (2008)

Relation between respiratory variations in pulse oximetry plethysmographic waveform amplitude and arterial pulse pressure in ventilated patients
por: Cannesson, Maxime, et al.
Publicado: (2005)

Comparative analysis on characteristics of two activated partial thromboplastin time reagents
por: Yasui, Yutaro, et al.
Publicado: (2022)

Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!
por: Santoro, Rita Carlotta, et al.
Publicado: (2023)

The Problem of the Lipoid Thromboplastins
por: Milstone, J. H.
Publicado: (1950)

Lipoid Thromboplastin and Trypsin
por: Milstone, J. H., et al.
Publicado: (1954)

Prediction of fluid responsiveness using respiratory variations in left ventricular stroke area by transoesophageal echocardiographic automated border detection in mechanically ventilated patients
por: Cannesson, Maxime, et al.
Publicado: (2006)

Is procalcitonin a valuable marker for identification of postoperative complications after coronary artery bypass graft surgery with cardiopulmonary bypass?
por: Baysal, A, et al.
Publicado: (2015)

Diabetes Mellitus Is Associated with Shortened Activated Partial Thromboplastin Time and Increased Fibrinogen Values
por: Zhao, Ying, et al.
Publicado: (2011)

Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time
por: Spencer, Akpan, et al.
Publicado: (2011)

Coronary Artery Disease Presentation and Its Association with Shortened Activated Partial Thromboplastin Time
por: Sotoudeh Anvari, Maryam, et al.
Publicado: (2018)

Falsely prolonged activated partial thromboplastin time – a pre- and post-analytical issue
por: Gils, Charlotte, et al.
Publicado: (2018)

A Patient with a Prolonged Activated Partial Thromboplastin Time and a Deep Intracerebral Haemorrhage
por: Schindhelm, Roger K., et al.
Publicado: (2012)

Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus
por: Sapkota, Binaya, et al.
Publicado: (2013)

Exogenous Magnesium Chloride Reduces the Activated Partial Thromboplastin Times of Lupus Anticoagulant-Positive Patients
por: Tokutake, Takayoshi, et al.
Publicado: (2016)

Prolonged activated partial thromboplastin time secondary to factor XII deficiency in two surgical patients
por: Moiz, Bushra, et al.
Publicado: (2021)

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population
por: Zhang, Fan, et al.
Publicado: (2022)

Cardiopulmonary Bypass
por: Rondelez, Luc, et al.
Publicado: (2010)

Normalization of Activated Partial Thromboplastin Time Correlates with Low Levels of Dabigatran in a Patient with Severe Sepsis
por: Højland, Rikke Ebenhard, et al.
Publicado: (2015)

Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients
por: Bachler, Mirjam, et al.
Publicado: (2019)

Reporting of activated partial thromboplastin time (aPTT): Could we achieve better comparability of the results?
por: Bronić, Ana, et al.
Publicado: (2021)

The missing slope: paradoxical shortening of activated partial thromboplastin time in a patient on unfractionated heparin therapy
por: Lapić, Ivana, et al.
Publicado: (2021)

Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
por: Monteagudo-Vela, María, et al.
Publicado: (2021)

The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2021)

Role of thromboelastography in the evaluation of septic shock patients with normal prothrombin time and activated partial thromboplastin time
por: Kim, Sang-Min, et al.
Publicado: (2021)

Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay
por: Billoir, Paul, et al.
Publicado: (2022)

Procalcitonin and C-Reactive Protein/Procalcitonin Ratio as Markers of Infection in Patients With Solid Tumors
por: Vassallo, Matteo, et al.
Publicado: (2021)

Effect of storage conditions on prothrombin time, activated partial thromboplastin time and fibrinogen concentration on canine plasma samples
por: Piccione, Giuseppe, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_d8j41euqmh62uqcu11i1fbbq20